Combinations of Anti-GITR Antibody and CD28 Superagonist Induce Permanent Allograft Acceptance by Generating Type 1 Regulatory T Cells
The authors reported the combined use of a CD28 superagonist and anti–glucocorticoid-induced tumor necrosis factor receptor–related protein monoclonal antibody (G3c) to induce Tr1 cells in vivo.
[Signal Transduction and Targeted Therapy] Scientists provide an update on recent clinical applications using either human pluripotent stem cells or mesenchymal stem cells derived from bone marrow, adipose tissue, or the umbilical cord for the treatment of human diseases.
[Scientific Reports] The authors suggested a novel strategy to treat triple negative breast cancer (TNBC) using mesenchymal stem cell-derived extracellular vesicles to transform the behaviors and cellular communication of TNBC cells with other non-cancer cells related to tumorigenesis and metastasis.
[Cancer Discovery] Researchers combined CAR T19 with the FDA-approved BCL-2-inhibitor, venetoclax, and demonstrated in vivo synergy in venetoclax-sensitive non-Hodgkin lymphoma.